| Croome | Hakeem | Chen | Song | Dokmak | Stauffer | Kantor | Conrad | Palanivelu | Khaled | Meng |
---|---|---|---|---|---|---|---|---|---|---|---|
Age (years) | 66.6 ± 9.6 | 67.0 ± 10.2 | – | 68.1 ± 7 | – | 69.9(40.6–84.8) | 65.9 ± 10.7 | 68(45–83) | 57.8 ± 2.0 | 65(35–78) | 60.0 ± 9.1 |
Sex (M/F) | 57/51 | 8/4 | – | – | – | 32/26 | – | 26/14 | 18/14 | 8/7 | 32/26 |
BMI | 27.4 ± 5.4 | 25.8 ± 3.7 | – | – | – | 25.9(17.7–49.6) | – | 23.9(14.9–34.1) | 24.9 ± 0.7 | 23.4(18–26) | 22.3 ± 3.0 |
Tumor size (cm) | 3.3 ± 1.0 | 2.0 ± 1.0 | 3.0 ± 0.9 | 2.8 ± 0.6 | 2.4(1.5–4) | 2.5(0.3–10.0) | – | 2.5 (0.3–8.0) | 3.3 ± 0.7 | 2.0(0.7–8.0) | 1.9(1.5–2.6) |
Retrieved LNs | 21.4 ± 8.1 | 20.7 ± 6.3 | 18.1 ± 6.6 | 15 ± 10 | 20(8–59) | 27(9–70) | 18.1 ± 9.5 | 18(6–53) | 18.9 ± 1.0 | 18(14–19) | 16(15–18) |
R0 rate | 77.8% | 75.0% | 94.7% | 72.7% | 60% | 84.5% | 79.1% | 87.5% | 96.9% | 86.7% | 100% |
Operative time (min) | 379.4 ± 93.5 | – | – | – | – | 518(313–761) | – | – | 359 ± 14 | 470(280–660) | 475(420–546) |
Blood loss (mL) | 492.4 ± 519.3 | – | – | – | – | 250(50–8500) | – | – | 250 ± 22 | 300(50–600) | 200(100–325) |
POPF | – | 16.7% | – | – | 20% | 11.8% | – | 30% | 15.6% | 20.0% | 55.2% |
Significant POPF | 11% | – | – | – | – | 7.8% | – | – | 6.3% | 20.0% | 13.8% |
Morbidity | 5.6% CD>2 | 58.3% | – | – | 53% | 53.4% | – | 95% | 25.0% | 40.0% | 15.5% CD>2 |
Hospital stay (days) | 6 (4–118) | 14.9 ± 6.6 | – | – | 15(6–53) | 6(4–68) | 10.2 ± 8.5 | 24.5(9–311) | 7(5–52) | 9.0(7–20) | 14.0(11.0–17.3) |
Readmission | – | – | – | – | – | 22.4% 90d | 6.8% 30d | – | 6.3% 90d | – | – |
Mortality | 0.9% 30d | 0% 30d | – | 0% 30d | 0% 90d | 3.4% 90d | 6.9% 90d | 5% 90d | 3.1% 90d | 0% 30d | 1.7% 30d |
Survival | MS: 25.3 m | 1,3,5y-DFS:100,92,83%; 1,3,5y-OS:100,92,75%. | – | 5y-OS: 53.6% | – | 1,2,3,4,5y-OS: 66.5,43.3,43.3%, 38.5,32.1% | MS: 20.7 m | MS: 35.5 m; 1,3,5y-DFS: 62.3, 37.9, 25.7%; 1,3,5y-OS: 80.5, 49.2, 39.7% | – | 1,3,5y-OS: 100, 80, 67% | MS: 45 m |